Item 2.01 | Completion of Acquisition or Disposition of Assets |
Sale of Summer Vista and Riverview Properties
As previously reported in a Current Report on Form8-K filed on January 28, 2020, CHP II Riverview FL Owner, LLC, a Delaware limited liability company, CHP II Riverview FL Tenant, LLC, a Delaware limited liability company, CHP II Summer Vista FL Owner, LLC, a Delaware limited liability company and CHP II Summer Vista FL Tenant, LLC, a Delaware limited liability company (collectively, the “Sellers”), each an operating subsidiary of CNL Healthcare Properties II, Inc. (the “Company”), entered into a Purchase and Sale Agreement and Joint Escrow Instructions (the “Purchase and Sale Agreement”) with WP CrossingsSR-FL Owner, LLC and WP SummerVistaSR-FL Owner, LLC, each a Delaware limited liability company and affiliate of Waypoint Residential, LLC (collectively the “Buyer”), for the sale (the “Sale”) of the Company’s two remaining senior assisted living facility properties (the “Properties”) for approximately $48,850,000 in cash, subject to certainpro-rations and other adjustments as described in the Purchase and Sale Agreement (the “Purchase Price”).
On February 28, 2020 (the “Closing Date”), the Sellers and Buyer consummated the Sale, which resulted in net cash proceeds to the Company of approximately $42.1 million after closing costs and repayment of indebtedness secured by the Properties sold (the “Sale Proceeds”). The Company intends to use a portion of the remainder of the Sale Proceeds to continue to execute on its stockholder-approved plan of liquidation and dissolution by satisfying outstanding liabilities. The Company anticipates making a final liquidating distribution to the Company’s stockholders and dissolving the Company on or before March 30, 2020. The Company has no remaining real estate assets.
Item 7.01 | Regulation FD Disclosure |
The Company wille-mail its stockholders’ financial advisors a letter notifying them of the closing of the Sale and advising of related matters. A copy of the letter to financial advisors is filed as Exhibit 99.1 to this Current Report on Form8-K and is incorporated herein by reference solely for the purposes of this Item 7.01 disclosure.
Pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”), the information contained in this Item 7.01 disclosure, including Exhibit 99.1 and the information set forth therein, is deemed to have been furnished and shall not be deemed to be “filed” under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall any of such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
By furnishing the information contained in this Item 7.01 disclosure, including Exhibit 99.1, the Company makes no admission as to the materiality of such information.
The Company’s advisor (the “Advisor”), its affiliates and related parties also are entitled to reimbursement of certain operating expenses in connection with their provision of services to the Company, including personnel costs, subject to the limitation that the Company will not reimburse the Advisor for any amount by which operating expenses exceed the greater of 2% of its average invested assets or 25% of its net income in any four consecutive fiscal quarters (“Expense Year”) unless approved by the independent directors. For the Expense Year ended December 31, 2019, the Company’s total operating expenses were in excess of this limitation by approximately $7,300. As of December 31, 2019, the Company had received cumulative approvals from its independent directors for total operating expenses in excess of this limitation of approximately $0.9 million. The Company’s independent directors determined that the higher relationship of operating expenses to average invested assets for the Expense Year ended December 31, 2019, was justified given the cost of operating a public company and the medical office building sale undertaken in the second quarter of 2019 in connection with the exploration of strategic alternatives, which further reduced the Company’s already limited number of investments.
Item 9.01 | Financial Statements and Exhibits |
| (b) | Pro forma financial information. |
The following unaudited pro forma condensed consolidated statement of net assets at September 30, 2019 illustrates the estimated effects of the sale of the Properties referred to in Item 2.01 above (the “Transaction”) as if it had occurred as of September 30, 2019.
The unaudited pro forma condensed consolidated statement of changes in net assets for the period from September 1, 2019 through September 30, 2019, and the unaudited condensed consolidated statements of operations for the eight months ended August 31, 2019 and for the year ended December 31, 2018 (the “Pro Forma Periods”), includes certain pro forma adjustments to illustrate the estimated effects of the Transaction as if it had occurred on the first day of each of the Pro Forma Periods.
The unaudited pro forma condensed consolidated statement of net assets, statement of changes in net assets and statements of operations are presented for informational purposes only and do not purport to be indicative of the Company’s financial results as if the Transaction reflected herein had occurred on the first date of or been in effect during the Pro Forma Periods. Further, the unaudited pro forma condensed consolidated statement of net assets, statement of changes in net assets and statements of operations should not be viewed as indicative of the Company’s financial results in the future; and they should be read in conjunction with the Company’s financial statements as filed with the SEC on Form10-Q for the nine months ended September 30, 2019 and on Form10-K for the year ended December 31, 2018.
2